EGFR and neoplasm: The combination of Defactinib and the EGFR-TKI gefitinib significantly reduces tumor volume in athymic nude mice bearing PC9GR tumors and decreases the expression levels of p-FAK, p-AKT, and p-ERK in tumor tissue [53].